|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0031809,
umls-concept:C0033681,
umls-concept:C0148199,
umls-concept:C0205179,
umls-concept:C0205460,
umls-concept:C0441655,
umls-concept:C0920321,
umls-concept:C1268567,
umls-concept:C1527249,
umls-concept:C1533714,
umls-concept:C1749467,
umls-concept:C2745888
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-3-22
|
|
pubmed:abstractText |
Plasma and serum biomarkers of angiogenesis and activated endothelial cells were evaluated to assess biological activity of PTK787/ZK 222584 (PTK/ZK), a novel oral angiogenesis inhibitor targeting all known vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:DrevsJJ,
pubmed-author:DuganMM,
pubmed-author:HenryAA,
pubmed-author:LaurentDD,
pubmed-author:LebwohlDD,
pubmed-author:LeeLL,
pubmed-author:MarméDD,
pubmed-author:MedingerMM,
pubmed-author:MrossKK,
pubmed-author:PinheiroJJ,
pubmed-author:Schmidt-GersbachC I MCI,
pubmed-author:StewardW PWP,
pubmed-author:ThomasA LAL,
pubmed-author:UngerCC,
pubmed-author:WoodJJ,
pubmed-author:ZirrgiebelUU
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
558-65
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15705616-Aged,
pubmed-meshheading:15705616-Biological Markers,
pubmed-meshheading:15705616-Clinical Trials, Phase II as Topic,
pubmed-meshheading:15705616-Colorectal Neoplasms,
pubmed-meshheading:15705616-Dose-Response Relationship, Drug,
pubmed-meshheading:15705616-Female,
pubmed-meshheading:15705616-Humans,
pubmed-meshheading:15705616-Male,
pubmed-meshheading:15705616-Middle Aged,
pubmed-meshheading:15705616-Phthalazines,
pubmed-meshheading:15705616-Protein Kinase Inhibitors,
pubmed-meshheading:15705616-Pyridines,
pubmed-meshheading:15705616-Receptors, Vascular Endothelial Growth Factor
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
|
|
pubmed:affiliation |
Tumor Biology Center, Freiburg, Germany. drevs@tumorbio.uni-freiburg.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
